Stein, Jason,Weiser, Michael,Capriotti, Joseph,Liang, Bo,Samson, C.
申请号：
NZ75184112
公开号：
NZ751841A
申请日:
2012.05.11
申请国别(地区):
NZ
年份:
2020
代理人:
摘要：
Disclosed are stable ophthalmic composition, comprising: 0.3 to 1% (w/w) polyvinylpyrrolidinone-iodine complex； 0.05 to 2% (w/w) non-steroidal anti-inflammatory drug (NSAID) bromfenac, or 0.05 to 2% (w/w) steroid selected from the group consisting of prednisolone acetate, loteprednol etabonate, difluprednate, hydrocortisone acetate, and combinations thereof； 0.005% to 0.02% (w/w) EDTA； 0.01 to 0.5% (w/w) sodium chloride； 0.02 to 0.1% (w/w) tyloxapol as a co-solvent/surfactant； 0.5% to 2% (w/w) sodium sulfate； and 0.1 to 0.5% (w/w) hydroxyethylcellulose as a viscosity increasing agent. These ophthalmic compositions are suitable for the treatment and/or prophylaxis of an eye disorder selected from the group consisting of a microorganism infection of at least one tissue of the eye, conjunctivitis, corneal abrasion, ulcerative infectious keratitis, epithelial keratitis, stromal keratitis and herpesvirus-related keratitis.
